Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide
Details : PHSU05 (ensereptide) is a synthetic peptide derived from human lactoferricin peptide, it inhibits the release of pro-inflammatory cytokines, such as IL-1β, IL-6 and Il-8 as well as TNF- alpha, to prevent post-surgical adhesions and scar formation.
Product Name : PXL01
Product Type : Peptide
Upfront Cash : Inapplicable
April 20, 2023
Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide
Details : PXL01 (ensereptide) is a synthetic peptide derived from human lactoferricin peptide, it inhibits the release of pro-inflammatory cytokines, such as IL-1β, IL-6 and Il-8 as well as TNF- alpha, to prevent post-surgical adhesions and scar formation.
Product Name : PXL01
Product Type : Peptide
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Pergamum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Recruited to Promore Pharma's Clinical Trial Regarding Scarring According to Plan
Details : The company's ensereptide program is focused on the prevention of skin scarring in conjunction with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of tissue adhesions after hand and...
Product Name : PXL01
Product Type : Peptide
Upfront Cash : Inapplicable
February 16, 2022
Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Pergamum AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FOL-005
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Bioskin GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FOL-005 is a modified, short version of the endogenous protein, osteopontin. The ongoing double-blind and placebo-controlled Phase IIa study examines the safety and efficacy of FOL-005 in a new, cream-like formulation.
Product Name : FOL-005
Product Type : Peptide
Upfront Cash : Inapplicable
January 28, 2021
Lead Product(s) : FOL-005
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Bioskin GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FOL-005
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Bioskin GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
All patients included in Follicum’s Phase II Study with FOL-005 for Stimulation of Hair Growth
Details : The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy of FOL-005 in a new, cream-like formulation. Patients themselves apply one of three different strengths of FOL-005 or placebo to the scalp once a day.
Product Name : FOL-005
Product Type : Peptide
Upfront Cash : Inapplicable
August 10, 2020
Lead Product(s) : FOL-005
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Bioskin GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 2 AFFIRM-35 trial in patients with moderate-to-severe psoriasis has shown excellent and sustained clinical response in patients. Based on these encouraging clinical results, clinical development program of ABY-035 has been expanded to include f...
Product Name : ABY-035
Product Type : Protein
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FOL-005
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Bioskin GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In two previous clinical studies, FOL-005 administered as an intradermal injection has been shown to be an effective and safe treatment for stimulation of hair growth.
Product Name : FOL-005
Product Type : Peptide
Upfront Cash : Inapplicable
March 06, 2020
Lead Product(s) : FOL-005
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Bioskin GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable